

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7435135

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	TRICLINIC LABS, INC.	10/15/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	ACADIA PHARMACEUTICALS INC.	
<b>Street Address:</b>	3611 VALLEY CENTRE DRIVE	
<b>Internal Address:</b>	SUITE 300	
<b>City:</b>	SAN DIEGO	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	92130	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	17862865
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(202) 371-2600	
<b>Email:</b>	MCrowley@sternekessler.com, MGROSS@sternekessler.com, jwalley@sternekessler.com	
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.	
<b>Address Line 1:</b>	1100 NEW YORK AVE, NW	
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005	
<b>ATTORNEY DOCKET NUMBER:</b>	4563.0050001	
<b>NAME OF SUBMITTER:</b>	MICHAEL F. GROSS III REG. NO. 64,974	
<b>SIGNATURE:</b>	/Michael F. Gross III, #64,974/	
<b>DATE SIGNED:</b>	07/15/2022	
<b>Total Attachments: 3</b>		
source=Assignment -Triclinic to Acadia - Acadia signed#page1.tif		
source=Assignment -Triclinic to Acadia - Acadia signed#page2.tif		
source=Assignment -Triclinic to Acadia - Acadia signed#page3.tif		

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, **Triclinic Labs, Inc.**, having a place of business at 2660 Schuyler Avenue, Suite A, Lafayette, Indiana 47905, (hereafter referred to as the Assignor) hereby sells and assigns to **Acadia Pharmaceuticals Inc.**, whose mailing address is 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130 (hereafter referred to as the Assignee), Assignor's entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **Crystalline Forms of Trofinetide** for which a provisional application for patent in the United States of America was filed on July 12, 2021 (also known as United States Application No. 63/220,660), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent applications, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any judicial or administrative proceeding, including but not limited to an interference, derivation, post-grant proceeding, or patent enforcement action (judicial or otherwise) related to the applications or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or

reexamination application(s) thereof or Letters Patent(s) therefor and to cooperate with the Assignee in every way possible in obtaining evidence and assisting with such judicial or administrative proceeding.

The Assignor hereby represents that the Assignor has full right to convey the entire interest herein assigned, and that the Assignor has not executed, and will not execute, any agreement in conflict therewith.


The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The Assignor hereby represents that the Assignor understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the Assignee, and are NOT the legal representatives of, and attorneys for, the Assignor.

This Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same Assignment. A signed copy of this Assignment delivered by e-mail or other means of electronic transmission will be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

IN WITNESS WHEREOF, executed by a duly authorized officer of the Assignor,

Triclinic Labs, Inc.

By  \_\_\_\_\_

Name: Shawn C. Comella

Title: Chief Executive Officer

Date: 15 October, 2021

SIGNED by a duly authorized officer on behalf of the said Assignee,

Acadia Pharmaceuticals Inc.

By: 

Name: Austin D. Kim

Title: EVP & General Counsel

Date: OCT 21, 2021

17431974.1